Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$55.45 USD

55.45
10,808,187

+1.13 (2.08%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Bristol-Myers Gets FDA Nod for Orencia's Label Expansion

by Zacks Equity Research

Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).

    Arpita Dutt headshot

    Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook

    by Arpita Dutt

    3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.

      Bristol-Myers' Opdivo Superior to Yervoy in Melanoma Study

      by Zacks Equity Research

      Bristol-Myers Squibb Company (BMY) announced that a phase III study, CheckMate-238, evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg met its primary endpoint at a planned interim analysis.

        Company News for July 06, 2017

        by Zacks Equity Research

        Companies in the News are: ORLY,BMY,MORE,PRPO

          Gilead's (GILD) HCV Drug Application Accepted in the EU

          by Zacks Equity Research

          Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

            Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

            by Zacks Equity Research

            Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

              AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

              by Zacks Equity Research

              AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

                Arpita Dutt headshot

                Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

                by Arpita Dutt

                All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

                  AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

                  by Zacks Equity Research

                  AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target

                    Exelixis's Cabometyx Positive for First-Line Kidney Cancer

                    by Zacks Equity Research

                    Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

                      Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada

                      by Zacks Equity Research

                      Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.

                        Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205

                        by Zacks Equity Research

                        Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.

                          J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use

                          by Zacks Equity Research

                          Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.

                            Arpita Dutt headshot

                            Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

                            by Arpita Dutt

                            Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.

                              Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

                              by Zacks Equity Research

                              Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.

                                Novartis, Bristol-Myers Collaborate for Opdivo Combination

                                by Zacks Equity Research

                                Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) collaborate for Opdivo combination therapies.

                                  Incyte Provides Updated Data on Cancer Combination Therapies

                                  by Zacks Equity Research

                                  Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.

                                    Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo

                                    by Zacks Equity Research

                                    Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.

                                      Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs

                                      by Zacks Equity Research

                                      Amgen, Inc. (AMGN) presented encouraging results from a phase III study, evaluating its marketed drug Xgeva (denosumab) for an expanded indication at the American Society of Clinical Oncology.

                                        Incyte Announces Data on Enzyme Inhibitor with Keytruda

                                        by Zacks Equity Research

                                        Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.

                                          Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU

                                          by Zacks Equity Research

                                          Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More

                                            by Arpita Dutt

                                            Lilly (LLY) posted positive data on Cyramza while Teva's migraine drug delivered positive results in a late-stage study.

                                              Why Is Bristol-Myers (BMY) Down 3.1% Since the Last Earnings Report?

                                              by Zacks Equity Research

                                              Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                Bristol-Myers Partners Array to Investigate Cancer Candidate

                                                by Zacks Equity Research

                                                Bristol-Myers Squibb Company (BMY) and Array BioPharma (ARRY) entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's binimetinib in combination with the former's Opdivo and Opdivo + Yervoy regimen.

                                                  Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer

                                                  by Zacks Equity Research

                                                  Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.